Results 301 to 310 of about 39,319 (333)
Some of the next articles are maybe not open access.
Ibrutinib and Cardiac Arrythmias
2021Patient was a 60-year-old male presented with palpitation. He had background history of diabetes type 2, obstructive sleep apnea on CPAP and hypertension.
openaire +2 more sources
Three years of ibrutinib in CLL
Blood, 2015In this issue of Blood, Byrd et al provide an important update on the prolonged efficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment.
openaire +4 more sources
2017
Ibrutinib (Imbruvica, Pharmacyclics, Janssen) is the first-in-class irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is positioned downstream of the BCR at the cell surface of normal and malignant B-cells. In 2013, the Food and Drug Administration (FDA) granted accelerated approval for the treatment of mantle-cell lymphoma (MCL), and in ...
openaire +2 more sources
Ibrutinib (Imbruvica, Pharmacyclics, Janssen) is the first-in-class irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is positioned downstream of the BCR at the cell surface of normal and malignant B-cells. In 2013, the Food and Drug Administration (FDA) granted accelerated approval for the treatment of mantle-cell lymphoma (MCL), and in ...
openaire +2 more sources
Risk of Major Bleeding with Ibrutinib
Clinical Lymphoma Myeloma and Leukemia, 2018The Bruton tyrosine kinase inhibitor, ibrutinib, is an effective therapy against mature B-cell malignancies. Although generally well tolerated, serious bleeding emerged during developmental clinical trials as an unexpected, although uncommon, adverse event.
Jeremy M Sen +8 more
openaire +3 more sources
Ibrutinib: targeting the hidden CLL
Blood, 2014In this issue of Blood , Herman et al elucidate the in vivo effects of ibrutinib (a BTK inhibitor) in various disease compartments of patients with chronic lymphocytic leukemia (CLL).[1][1] The study validates the differential impact of ibrutinib in various tumor compartments of patients treated ...
openaire +3 more sources
Current Treatment Options in Oncology, 2014
The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) includes the use of chemoimmunotherapy and/or radiation therapy. When patients with these diseases relapse or are refractory to therapy, their diseases are considered incurable outside of the setting of an autologous or ...
Kristie A. Blum, Kami J. Maddocks
openaire +2 more sources
The standard frontline therapy for diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) includes the use of chemoimmunotherapy and/or radiation therapy. When patients with these diseases relapse or are refractory to therapy, their diseases are considered incurable outside of the setting of an autologous or ...
Kristie A. Blum, Kami J. Maddocks
openaire +2 more sources
Ibrutinib for Mantle Cell Lymphoma
Future Oncology, 2016Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma. Ibrutinib is a first-in-class, oral inhibitor of Bruton's tyrosine kinase which acts by downstream inhibition of the B-cell receptor. Early clinical trials have demonstrated excellent tolerability and a modest side-effect profile in relapsed/refractory MCL.
David L. Tucker, Simon Rule
openaire +3 more sources
Ibrutinib promising in subtype of DLBCL [PDF]
The Lancet Oncology, 2015 Patients with the activated B-celllike (ABC) subtype of diff use large B-cell lymphoma were more likely to respond to ibrutinib than were those with the germinal centre B-celllike (GCB) subtype of the disease, according to results of a phase 2 study.
openaire +2 more sources
Ibrutinib for the treatment of Waldenström macroglobulinemia
Expert Review of Hematology, 2015Waldenström macroglobulinemia (WM) is a B-cell non-Hodgkin lymphoma (NHL) characterized by IgM monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Until recently, there was no drug specifically approved for WM by the US FDA, leading to wide variations in therapeutic strategies across the globe.
Prashant Kapoor +3 more
openaire +3 more sources
Ibrutinib-Induced Neutrophilic Dermatosis
The American Journal of Dermatopathology, 2018Abstract: We report the case of a 64-year-old woman treated with ibrutinib for a chronic lymphocytic leukemia with 17p deletion, who developed several erythematous, painful, and papulo-nodular skin lesions in the limbs, neck, and face. The skin biopsy was consistent with the diagnosis of neutrophilic dermatosis.
Khadija Cherif-Rebai +3 more
openaire +2 more sources